Summary and Analysis of Clinical Practice Guidelines for Proton Pump Inhibitors in China
WU Jun-biaoa, NI Xiao-jiab, CHEN Shea, DUAN Xiao-honga, WANG Xiao-huia, WANG Ying-yana, LAI Xiao-xiaoa, GUO Xin-fengb, LIN Huaa, LUO Yi-nia*
a. Department of Clinical Pharmacy; b. EBM & Clinical Research Service Group, The Second College of Clinical Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510120, China
Abstract��OBJECTIVE To know about the application of proton pump inhibitors (PPI)in different diseases and provide the essential references for the use of PPI, clinical practice guidelines for PPI in China were sort out and analyzed. METHODS The clinical practice guidelines of PPI were searched and sort out according to the categories, levels of evidence of effectiveness and safety, strength of recommendations of guidelines, and so on. RESULTS Seventeen clinical practice guidelines, which are related to the prevention and cure in gastrointestinal disease, were included in our researches. Except five guidelines, the rest of them were not evidence-based clinical guidelines. CONCLUSION The recommendations of the clinical practice guideline for PPI are not just very clear, which lead to disorder of PPI clinical medication, the urgent need is to develop relevant provisions to further regulate the PPI medication.
���,��С��,����,������,��С��,��ӱ��,������,���·�,�ֻ�,��ܲ��. �ҹ����ӱ����Ƽ��ٴ�ʵ��ָ�ϵĸſ������[J]. �й�ҩѧ��־, 2017, 52(18): 1649-1654.
WU Jun-biao, NI Xiao-jia, CHEN She, DUAN Xiao-hong, WANG Xiao-hui, WANG Ying-yan, LAI Xiao-xiao, GUO Xin-feng, LIN Hua, LUO Yi-ni. Summary and Analysis of Clinical Practice Guidelines for Proton Pump Inhibitors in China. Chinese Pharmaceutical Journal, 2017, 52(18): 1649-1654.
CHEN X Q, JIN Y G, TANG G. New Materia Medica (�±�ҩ��ѧ)[M]. Vol 17. Beijing:People��s Medical Publishing House,2011:34.
[2]
TAN Y D X, CAI J, FENG W Y. Utilization of proton pump inhibitors in six areas in China[J]. Chin Pharm J (�й�ҩѧ��־), 2015, 50(9):821-823.
[3]
LAZARUS B, CHEN Y, WILSON F P, et al. Proton pump inhibitor use and the risk of chronic kidney disease[J]. JAMA Intern Med, 2016, 176(2):238-246.
[4]
XIE Y, BOWE B, LI T, et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD[J]. J Am Soc Nephrol, 2016, 27(10):3153.
[5]
PENG Y L, LUO J C. The benefits and risks of proton pump inhibitor therapy[J]. J Chin Med Assoc, 2016, 79(1):1-2.
[6]
CHENG Z, LI J X, GAO Y H. Special evaluation of the proton pump inhibitors [J]. Chin J Clin Rational Drug Use (�ٴ�������ҩ��־), 2016, 9(6):31-32.
[7]
CHEN L Y, HUANG T G, SONG A H. The analysis of unreasonable prescription of oral proton pump inhibitor in outpatient service[J]. Chin J Clin Rational Drug Use (�ٴ�������ҩ��־), 2011, 4(1):123-124.
[8]
ZHU A G, WANG J, ZHANG G W. Analysis of the application of proton pump inhibitors in our hospital from 2011 to 2013[J]. J China Pharm (�й�ҩ��), 2015, 26(14):1914-1917.
[9]
BAI Y, LI Y Q, REN X, et al. Expert advice on stress ulcer prevention (2015 edition)[J]. Natl Med J China(�л�ҽѧ��־), 2015, 95(20):1555-1557.
[10]
ZHAO Y P. Prevention and treatment of stress mucosal lesions��consensus of general surgery experts in China(2015)[J]. Chin J Prac Surg (�й�ʵ�������־), 2015, 39(7):728-730.
[11]
CHEN Y H, HOU X H, XIAO Y L. Expert consensus of gastroesophageal reflux disease in China [J]. Chin J Gastroenterol(θ����ѧ), 2015, 20(03):155-168.
[12]
CSGE. Consensus on the diagnosis and treatment of Barrett esophagus (Revised edition, June 2011, Chongqing)[J]. Chin J Gastroenterol(θ����ѧ), 2011, 16(8):485-486.
[13]
WANG X P, LI Z S, YUAN Y Z, et al. Guidelines for diagnosis and treatment of acute pancreatitis in China (2013, Shanghai)[J]. Chin J Pract Intern Med(�й�ʵ���ڿ���־), 2013, 33(7):530-535.
[14]
Division of pancreatic surgery of Chinese Medical Association. Guidelines for the diagnosis and treatment of chronic pancreatitis (2014)[J]. Chin J Gen Surg(�л���ͨ�����־), 2015, 30(5):416-421.
[15]
The Helicobacter pylori Digestive Disease Branch of Chinese Medical Association of Helicobacter pylori bacteria. Fourth national consensus report on treatment of Helicobacter pylori infection [J]. Chin J Gastroenterol(θ����ѧ), 2012, 17(10):618-625.
[16]
CSGE.Consensus opinion on chronic gastritis in China (2012, Shanghai)[J]. Chin J Dig(�л�������־), 2013, 33(1):5-16.
[17]
Gastrointestinal dynamics group of Gastroenterology branch of Chinese Medical Association. Expert consensus on functional dyspepsia in China (2015, Shanghai)[J]. Chin J Dig(�л�������־),2016, 36(4):217-229.
[18]
XU X Y, DI H G, JIA J D, et al. Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol(�ٴ��ε�����־), 2016, 32(2):203-219.
[19]
Chinese Medical Association.Guidelines for the diagnosis and treatment of acute non variceal upper gastrointestinal bleeding (2015, Nanchang)[J]. Natl Med J China (�л�ҽѧ��־), 2016, 96(4):254-259.
[20]
Digestive endoscopy Association of Chinese Medical Association. Expert consensus on screening and endoscopic diagnosis and treatment of early esophageal cancer in China (2014, Beijing)[J]. Chin J Gastroenterol(θ����ѧ), 2015, 20(4):220-240.
[21]
Chinese Medical Association. Consensus on the screening and diagnosis and treatment of early squamous cell carcinoma and precancerous lesions in China (2015,Beijing)[J]. Chin Med(�й�ҽ��), 2016, 51(1):17-31.
[22]
CRPC, ASMC.Guidelines for the prevention and treatment of vomiting associated with cancer therapy (2014 Edition)[J]. Chin Clin Oncol (�ٴ�����ѧ��־), 2014, 19(3):263-273.
[23]
Ministry of Health. Guidelines for the clinical use of glucocorticoids[J]. Chin J Endocrinol Metab(�л��ڷ��ڴ�л��־), 2012, 28(1):38-45.
[24]
Chinese expert consensus group on prevention and treatment of impaired digestive tract in antiplatelet drugs. Expert consensus on the prevention and treatment of antiplatelet drugs in digestive tract injury (2012 Edition)[J]. Chin J Intern Med(�л��ڿ���־), 2013, 52(3):264-270.
[25]
Group of experts on the prevention and treatment of digestive tract injury by antithrombotic therapy.Chinese expert advice on prevention and treatment of digestive tract injury with antithrombotic therapy (2016,Beijing)[J]. Chin J Intern Med(�л��ڿ���־), 2016, 55(7):564-567.
[26]
NUMANS M E, LAU J, DE WIT N J, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease:a Meta-analysis of diagnostic test characteristics[J]. Ann Intern Med, 2004, 140(7):518-527.
[27]
SUGANO K, TACK J, KUIPERS E J, et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015, 64(9):1353-1367.
[28]
LANZA F L, CHAN F K, QUIGLEY E M. Guidelines for prevention of NSAID-related ulcer complications[J]. Am J Gastroenterol, 2009, 104(3):728-738.
[29]
LAINE L, NAGAR A. Long-term PPI use:balancing potential harms and documented benefits[J]. Am J Gastroenterol, 2016, 111(7):913-915.
[30]
CHEN C H, LIN H C, LIN H L, et al. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease[J]. J Microbiol Immunol Infect, 2015, 48(4):390-396.
[31]
RO Y, EUN C S, KIM H S, et al. Risk of clostridium difficile infection with the use of a proton pump inhibitor for stress ulcer prophylaxis in critically �� patients[J]. Gut Liver, 2016, 10(4):581-586.
[32]
GELLER J L, ADAMS J S. Proton pump inhibitor therapy and hip fracture risk[J]. JAMA, 2007, 297(13):1429, 1429-1430.
2017, Vol. 52 
